News
Monjuvi, combined with Revlimid and Rituxan, significantly improves progression-free survival in relapsed/refractory follicular lymphoma, as shown in the inMIND trial. The trial reported a median ...
Epkinly, Rituxan, and Revlimid combination reduces disease progression risk by 79% in relapsed/refractory follicular lymphoma patients. The EPCORE FL-1 trial supports global regulatory submissions and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback